Leukotrienes as mediators of airway obstruction and inflammation in asthma.
Dahlén
B
B
Department of Physiology and Pharmacology, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden.
Dahlén
S E
SE
D000402:Airway Obstruction / Q000503:physiopathology*; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology; D001095:Arachidonic Acids / Q000378:metabolism; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D007249:Inflammation; D020024:Leukotriene Antagonists; D015289:Leukotrienes / Q000502:physiology*
D018927:Anti-Asthmatic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D001241:Aspirin